ストックスクリーナーアプリを入手
34.26
0.58%
-0.20
前日終値:
$34.46
開ける：
$34.38
24時間の取引高:
288.80K
Relative Volume:
0.69
時価総額：
$2.79B
収益：
$13.17M
当期純損益:
$-199.06M
株価収益率:
-12.50
EPS:
-2.74
ネットキャッシュフロー:
$-156.53M
1週間 パフォーマンス:
-3.06%
1か月 パフォーマンス:
-10.57%
6か月 パフォーマンス:
-11.36%
1年 パフォーマンス:
-20.42%
1日の値動き範囲:
$33.83
$34.80
1週間の範囲:
$33.62
$36.51
52週間の値動き範囲:
$33.27
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
名前
Xenon Pharmaceuticals Inc
セクター
電話
(604) 484-3300
住所
200 - 3650 GILMORE WAY, BURNABY
XENE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
34.26 | 2.79B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-10-01 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-04 | 開始されました | Citigroup | Buy |
| 2023-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 開始されました | Goldman | Buy |
| 2022-12-12 | 開始されました | Cowen | Outperform |
| 2022-11-28 | 開始されました | Wells Fargo | Overweight |
| 2022-10-19 | 開始されました | Raymond James | Outperform |
| 2022-08-29 | 開始されました | BofA Securities | Buy |
| 2022-07-21 | 開始されました | JP Morgan | Overweight |
| 2021-10-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-10-02 | 開始されました | SVB Leerink | Outperform |
| 2020-07-21 | 開始されました | Needham | Buy |
| 2020-06-01 | 再開されました | Jefferies | Buy |
| 2020-03-25 | 開始されました | Wedbush | Outperform |
| 2020-01-08 | 開始されました | William Blair | Outperform |
| 2019-09-20 | 開始されました | Guggenheim | Buy |
| 2018-08-08 | 繰り返されました | Stifel | Buy |
| 2017-03-13 | 開始されました | Jefferies | Buy |
| 2016-10-21 | 開始されました | Stifel | Buy |
| 2016-09-26 | 開始されました | Guggenheim | Buy |
| 2016-04-14 | 繰り返されました | Jefferies | Buy |
| 2015-10-30 | 再開されました | Jefferies | Buy |
| 2014-12-02 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Xenon Pharmaceuticals Inc (XENE) 最新ニュース
StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Hold - Defense World
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Swiss National Bank - Defense World
(XENE) Trading Advice - Stock Traders Daily
Xenon Pharmaceuticals announces executive changes - MSN
Bank of New York Mellon Corp Sells 2,294 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
What is William Blair’s Estimate for XENE Q1 Earnings? - Defense World
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals at Stifel Forum: Strategic Advances in CNS By Investing.com - Investing.com Canada
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role - MSN
(XENE) Trading Signals - Stock Traders Daily
Xenon Pharmaceuticals to Present at Stifel 2025 Virtual CNS Forum - TipRanks
Xenon to Present at Stifel 2025 Virtual CNS Forum - The Manila Times
Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of “Buy” by Brokerages - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals appoints PwC as new auditor - Investing.com
Xenon Pharmaceuticals appoints PwC as new auditor By Investing.com - Investing.com South Africa
New KCNQ2/3 activators disclosed in Xenon Pharmaceuticals patents - BioWorld Online
Q1 Earnings Forecast for XENE Issued By HC Wainwright - Defense World
Equities Analysts Offer Predictions for XENE Q1 Earnings - Defense World
What is Leerink Partnrs’ Estimate for XENE Q1 Earnings? - Defense World
(XENE) On The My Stocks Page - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 1-Year Low – Time to Sell? - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Earns “Outperform” Rating from William Blair - Defense World
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
HC Wainwright Has Pessimistic Outlook of XENE Q1 Earnings - MarketBeat
Strategic Growth Potential and Upcoming Catalysts Drive Buy Rating for Xenon Pharmaceuticals - TipRanks
Xenon Pharmaceuticals price target lowered to $42 from $43 at Wedbush - TipRanks
Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
RBC Capital Adjusts Xenon Pharmaceuticals Price Target to $58 From $56, Maintains OutperformSpeculative Risk Rating - Marketscreener.com
Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $60 From $67, Maintains Buy Rating - Marketscreener.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2024 Earnings Call Transcript - Insider Monkey
Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Xenon Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Xenon Pharmaceuticals Advances Clinical Pipeline Amid Financial Losses - TipRanks
Xenon Pharmaceuticals reports Q4 EPS (84c), consensus (84c) - TipRanks
Earnings call transcript: Xenon Pharmaceuticals Q4 2024 sees slight EPS beat - Investing.com
Xenon Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xenon Pharmaceuticals Q4 Net Loss Widens -February 27, 2025 at 05:13 pm EST - Marketscreener.com
Earnings Flash (XENE) Xenon Pharmaceuticals Q4 Loss Per Share $-0.84 vs. FactSet Est Loss $-0.88 - Marketscreener.com
Xenon Pharmaceuticals: Q4 Earnings Snapshot -February 27, 2025 at 04:20 pm EST - Marketscreener.com
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update - The Manila Times
Xenon Pharmaceuticals Inc. Announces Resignation of Sherry Aulin as Chief Financial Officer, Effective June 30, 2025 - Marketscreener.com
Can Xenon's $754M War Chest Fuel Its Epilepsy Breakthrough? Phase 3 Data Coming 2025 - StockTitan
Xenon CFO Resignation Amidst Strong Financial Outlook - TipRanks
HC Wainwright Issues Pessimistic Estimate for XENE Earnings - Defense World
What To Expect From Xenon Pharmaceuticals Inc (XENE) Q4 2024 Ear - GuruFocus.com
What To Expect From Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings - Yahoo Finance
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference - The Manila Times
Xenon Pharmaceuticals Inc (XENE) 財務データ
収益
当期純利益
現金流量
EPS
Xenon Pharmaceuticals Inc (XENE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Option Exercise |
17.76 |
16,315 |
289,754 |
46,468 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Option Exercise |
17.76 |
16,217 |
288,014 |
47,519 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Sale |
40.20 |
22,468 |
903,214 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Sale |
40.50 |
16,315 |
660,806 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Sale |
40.08 |
16,217 |
649,977 |
31,302 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):